Thomas Nicole, García-Prieto Carlos A, Dreval Kostiantyn, Hilton Laura K, Abramson Jeremy S, Bartlett Nancy L, Bethony Jeffrey, Bowen Jay, Bryan Anthony C, Casper Corey, Dyer Maureen A, Gastier-Foster Julie M, Gerrie Alina S, Greiner Timothy C, Griner Nicholas B, Gross Thomas G, Harris Nancy, Irvin John D, Jaffe Elaine S, Leal Fabio E, Mbulaiteye Sam M, Mullighan Charles G, Mungall Andrew J, Mungall Karen L, Namirembe Constance, Noy Ariela, Ogwang Martin D, Orem Jackson, Ott German, Petrello Hilary, Reynolds Steven J, Swerdlow Steven H, Traverse-Glehen Alexandra, Wilson Wyndham H, Marra Marco A, Staudt Louis M, Scott David W, Esteller Manel, Morin Ryan D
Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, Canada.
Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain.
Blood Cancer Discov. 2025 Jul 1;6(4):325-342. doi: 10.1158/2643-3230.BCD-24-0240.
The genetic subtypes of Burkitt lymphoma have been defined, but the role of epigenetics remains to be comprehensively characterized. We searched genomic DNA from 218 patients across four continents for recurrent DNA methylation patterns and their associations with clinical and molecular features. We identified DNA methylation patterns that were not fully explained by the Epstein-Barr virus status or mutation status, leading to two epitypes described here as HypoBL and HyperBL. Each is characterized by distinct genomic and clinical features including global methylation, mutation burden, aberrant somatic hypermutation, and survival outcomes. Methylation, gene expression, and mutational differences between the epitypes support a model in which each arises from a distinct cell of origin. These results, pending validation in external cohorts, point to a refined risk assessment for patients with Burkitt lymphoma who may experience inferior outcomes.
Burkitt lymphoma can be divided into two epigenetic subtypes (epitypes), each carrying distinct biological, transcriptomic, genomic, and clinical features. Epitype is more strongly associated with clinical and mutational features than the Epstein-Barr virus status or genetic subtype, highlighting an important additional layer of Burkitt lymphoma pathogenesis.
伯基特淋巴瘤的基因亚型已被定义,但表观遗传学的作用仍有待全面表征。我们在来自四大洲的218名患者的基因组DNA中搜索复发性DNA甲基化模式及其与临床和分子特征的关联。我们鉴定出一些DNA甲基化模式,这些模式无法完全由爱泼斯坦-巴尔病毒状态或突变状态解释,从而产生了这里描述为低甲基化伯基特淋巴瘤(HypoBL)和高甲基化伯基特淋巴瘤(HyperBL)的两种表观类型。每种表观类型都具有独特的基因组和临床特征,包括整体甲基化、突变负荷、异常体细胞超突变和生存结果。表观类型之间的甲基化、基因表达和突变差异支持一种模型,即每种表观类型都源自不同的起源细胞。这些结果有待在外部队列中验证,为可能预后较差的伯基特淋巴瘤患者提供了更精确的风险评估。
伯基特淋巴瘤可分为两种表观遗传亚型(表观类型),每种都具有独特的生物学、转录组学、基因组和临床特征。表观类型与临床和突变特征的关联比爱泼斯坦-巴尔病毒状态或基因亚型更强,突出了伯基特淋巴瘤发病机制中一个重要的附加层面。